Attached files

file filename
EX-99.1 - PRESS RELEASE - CorMedix Inc.crmd_ex991.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 23, 2013

CORMEDIX INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
 
001-34673
 
20-5894890
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
745 Rt. 202-206, Suite 303, Bridgewater, NJ
 
08807
(Address of Principal Executive Offices)
 
(Zip Code)

Registrant’s Telephone Number, Including Area Code: (908) 517-9500

 
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
Item 8.01.
Other Events.

On December 23, 2013, CorMedix Inc. issued a press release announcing that we received official minutes from our pre-IND meeting with the U.S. Food and Drug Administration concerning the development of Neutrolin® in the Unites States.

A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits
 
Exhibit No.    Description
     
99.1    Press release dated December 23, 2013.
 
 
 
2

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  CORMEDIX INC.  
       
Date: December 23, 2013  
By:
/s/ Randy Milby  
  Name: Randy Milby  
  Title: Chief Executive Officer  
       

 
 


3